Insiders Trades
GVS SpA Stock: price and insider trades · Italy
GVS SpA: what insiders have been doing
Every trade that managers of GVS SpA disclose to Consob is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, the company's managers filed 14 filings, from 5 insiders.
There is no open-market purchase to report; the filings show 2 sales worth €9,385 by 2 insiders. Biggest ticket of the year: €8,616, sold by Claudio Tonielli and made public on 27 May 2026 (0.0011% of market cap).
Publication is fast: at least half of the trades appear on Consob on the same day. For comparison, MAR article 19 gives managers three business days to notify a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (224 companies, median 3 filings), a count of 14 filings is above the norm. Since 2025, the database holds no purchases and 2 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Consob. They describe what insiders did and are not a recommendation.
Insider Decl.
15
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€9,385
2 ops. · all time
Who traded when
BuySaleChief Operating Officer Matteo Viola1 sale
Claudio Tonielli1 sale
Analyst consensus: bullish or bearish?
Analysts rate GVS SpA Strong Buy (bullish), based on 5 analysts. Average price target: €5.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,557 of 24,148 companies
48.0
score / 100
Value41
Quality55
FCF yld1.2%
Earn yld1.9%
EV/EBITDA15.7x
ROE9.3%
Gross mgn68%
Net mgn4.3%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€5.31
Analyst consensus
5 analystsStrong buy
€5.00Target €5.86(+10%)€7.50
Income statement
Revenue€424.7M
Gross profit€289.9M68% margin
EBITDA€81.9M19% margin
Net income€18.4M9.6% margin
Valuation
PER (trailing)24.1x
PER (forward)17.7x
P/Book2.2x
Beta1.06
Balance sheet & cash
Market cap€972.3M
Total debt€310.7M
Free Cash Flow€11.3M
Debt / Equity57%
Profitability & ownership
ROE9.3%
ROA4.9%
% insiders65.9%
% institutions14.9%
Last declaration on 8 July 2026
Declarations15 total
8,140 shares@ €4.300.0041% mcap100.0% of flowShareXMILISIN IT0005411209CONSOB:186735
9,000 shares@ €4.300.0045% mcap100.0% of flowShareXMILISIN IT0005411209CONSOB:186734
1,934 shares@ €4.4550.0011% mcap100.0% of flowShareXMILISIN IT0005411209CONSOB:184992
178 shares@ €4.320.0001% mcap100.0% of flowShareXMILISIN IT0005411209CONSOB:184539
23,912 shares0ShareXMILISIN IT0005411209CONSOB:181798
45,306 shares0ShareXMILISIN IT0005411209CONSOB:181797
45,306 shares0ShareXMILISIN IT0005411209CONSOB:181796
45,306 shares0ShareXMILISIN IT0005411209CONSOB:181792
45,306 shares0ShareXMILISIN IT0005411209CONSOB:181790
45,306 shares0ShareXMILISIN IT0005411209CONSOB:181787
45,306 shares0ShareXMILISIN IT0005411209CONSOB:181786
67,959 shares0ShareXMILISIN IT0005411209CONSOB:181784
67,959 shares0ShareXMILISIN IT0005411209CONSOB:181783
218,980 shares0ShareXMILISIN IT0005411209CONSOB:181782
15 of 15 declarations
About GVS SpA
GVS S.p.A. is an Italian industrial company listed on Borsa Italiana (FTSE MIB), headquartered in Bologna, Italy. Founded in 1979, GVS has evolved from a supplier of healthcare components into a global specialist in advanced filtration solutions. The company’s strategy is built on innovation, vertical integration, and a “glocal” operating model: close proximity to customers in local markets, supported by a globally distributed manufacturing and commercial network.
Today, GVS serves several end markets, primarily Healthcare & Life Sciences, Energy & Mobility, and Health & Safety. These are highly regulated industries where product performance, reliability, and compliance are critical. Its portfolio includes filtration solutions and components used in medical devices, laboratory analysis, transfusion medicine, safety applications, mobility-related systems, and a broad range of industrial uses. The group emphasizes product development, process innovation, and proprietary know-how, supported by R&D capabilities, patents, and integrated production processes from design through delivery.
Read moreShow less
From a competitive standpoint, GVS is positioned among the world’s leading manufacturers of advanced filtration solutions for critical applications. Its differentiation lies in its specialization, its ability to serve demanding technical applications, and its international footprint. The group operates manufacturing sites in Italy, the United Kingdom, Brazil, the United States, China, Mexico, Romania, and Puerto Rico, alongside a wide network of commercial offices worldwide. This geographic diversification supports customer proximity and reduces reliance on any single market.
Recent developments are important for investors. In January 2025, GVS completed the acquisition of Haemonetics’ whole blood business, strengthening its exposure to transfusion medicine and broadening its healthcare offering. Management also highlighted in first-quarter 2025 disclosures that the integration of this business should contribute to revenue ramp-up, while the group continues industrial efficiency initiatives. Reported results indicate improving profitability and ongoing attention to balance sheet discipline. Overall, GVS combines defensive exposure to healthcare and laboratory end markets with international growth potential and an execution-focused industrial profile.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
